Evaluating DR2 agonism as a potential therapeutic approach to substance abuse and traumatic brain injury

$75,000U54FY2025MDNIH

Xavier University Of Louisiana, New Orleans LA

Investigators

Guangdi Wangcontact Christopher Williams

Linked publications, trials & patents

Paper 39772000 Paper 39487279 Paper 39361251 Paper 39108777 Paper 38932579 Paper 38856747 Paper 38207244 Paper 38196640 Paper 38133447 Paper 38131983 Paper 38109241 Paper 38064314 Paper 37963190 Paper 37944099 Paper 37847647 Paper 37812742 Paper 37721967 Paper 37569001 Paper 37427255 Paper 37426253 Paper 37375297 Paper 37350741 Paper 37275479 Paper 37242518 Paper 37176114 Paper 37139178 Paper 37111288 Paper 37043688 Paper 36971286 Paper 36855065 Paper 36797297 Paper 36583130 Paper 36554864 Paper 36554617 Paper 36420104 Paper 36321236 Paper 35964061 Paper 35945714 Paper 35944852 Paper 35847251 Paper 35811930 Paper 35772635 Paper 35755802 Paper 35732666 Paper 35642005 Paper 35579936 Paper 35561191 Paper 35499138 Paper 35477142 Paper 35465688 Paper 35454120 Paper 35444938 Paper 35444723 Paper 35392296 Paper 35377529 Paper 35320094 Paper 35255412 Paper 34991418 Paper 34965922 Paper 34959763 Paper 34882539 Paper 34521520 Paper 34475500 Paper 34451816 Paper 34401362 Paper 34357750 Paper 34313616 Paper 34291559 Paper 34205781 Paper 34202383 Paper 34149955 Paper 34056422 Paper 33984189 Paper 33974537 Paper 33963802 Paper 33869913 Paper 33866309 Paper 33800952 Paper 33798117 Paper 33758158 Paper 33753258 Paper 33752648 Paper 33718123 Paper 33647990 Paper 33577454 Paper 33562262 Paper 33528293 Paper 33517263 Paper 33261898 Paper 33233396 Paper 33204588 Paper 32992554 Paper 32968620 Paper 32947018 Paper 32938283 Paper 32929407 Paper 32586210 Paper 32574662 Paper 32527558 Trial NCT03869216

Abstract

Title: Evaluating DR2 agonism as a potential therapeutic approach to substance abuse and traumatic brain injury Abstract Substance use disorder (SUD) and traumatic brain injury (TBI) are inextricably and bidirectionally linked. SUD is one of the strongest predictors of TBI, and a substantial proportion of TBIs occur in addicted individuals. An inverse relationship is also emerging, such that TBI can serve as a risk factor for, or modulate the course of, SUD. Critically, substance use after TBI is a key predictor of rehabilitation outcomes, prognosis, and additional head injuries. Currently, there are no FDA-approved treatment options for either TBI or SUDs associated with psychostimulants. DR2 agonism has potentially reemerged as a potential therapeutic approach under both conditions because of their relatively low abuse liability profile. Using a translational approach, the objective of this application is to explore the therapeutic potential of DR2 agonism in TBI and substance use. This application will seek to answer these research questions: 1) Does DR2 mitigate the neuroinflammatory state associated with TBI and substance use and 2) Does D2 agonism influence the proteogenomic relationship in either TBI and/or SUDs. The objective of this application will be accomplished by addressing the following: Aim 1: Determine the neuroprotective potential of dopaminergic agonists in an in vitro ischemic/substance use model of the neurovascular unit and Aim 2: Define the proteogenomic profiles of D2 agonism on TBI/SUD protein expression by cutting- edge RNA-seq and proteomics. This study is innovative because it employs a novel, dynamic blood-brain barrier platform capable of recapitulating human in vivo physiological parameters. This study is significant because it will highlight specific signaling and gene expression profiles associated with TBI, and substance use to develop specific treatment endpoints The long-term goal of this is to develop data for further proposal preparation and to identify new molecular targets for further therapeutic development.

View original record on NIH RePORTER →